Concepedia

Maximilian von Eynatten

MV

80

Publications

13.7K

Citations

44

H-Index

2002

Active since

Affiliations

Boehringer Ingelheim (Germany)(Current)

Heidelberg University

University of Würzburg

University of Toronto

Boehringer Ingelheim (United Kingdom)

Maximilian von Eynatten is an author at Boehringer Ingelheim (Germany) specializing in medicine, diabetes, and metabolic syndrome.

Top concepts

Publications per year

2002–2023

80

Publications

80

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes

Christoph Wanner, Silvio E. Inzucchi, John M. Lachin et al. · New England Journal of Medicine · 2016 · 3.5K citations · Full text

Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus

David Z.I. Cherney, Bruce A. Perkins, Nima Soleymanlou et al. · Circulation · 2013 · 1.3K citations · Full text

Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk

Julio Rosenstock, Vlado Perkovic, Odd Erik Johansen et al. · JAMA · 2018 · 1K citations · Full text

A mechanism converting psychosocial stress into mononuclear cell activation

Angelika Bierhaus, Jutta M. Wolf, Martin Andrassy et al. · Proceedings of the National Academy of Sciences · 2003 · 910 citations · Full text

, , +21

Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes

Julio Rosenstock, Steven E. Kahn, Odd Erik Johansen et al. · JAMA · 2019 · 578 citations · Full text

Rows per page

1–5 of 80